NTRA Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of -11.3% compared to Natera's net margin of -121.19%. Natera's return on equity of -21.3% beat Exact Sciences's return on equity of -34.11%.

Natera has a consensus price target of $187.72, signalling upside risk potential of 26.8%. On the other hand Exact Sciences has an analysts' consensus of $67.33 which suggests that it could grow by 51.48%. Given that Exact Sciences has higher upside potential than Natera, analysts believe Exact Sciences is more attractive than Natera.

Natera has a beta of 1.804, which suggesting that the stock is 80.37% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.136, suggesting its more volatile than the S&P 500 by 13.608%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Natera quarterly revenues are $476.1M, which are smaller than Exact Sciences quarterly revenues of $713.4M. Natera's net income of -$53.8M is higher than Exact Sciences's net income of -$864.6M. Notably, Natera's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 10.88x versus 2.97x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of -11.3% compared to Natera's net margin of -55%. Natera's return on equity of -21.3% beat Guardant Health's return on equity of -8518.58%.

Natera has a consensus price target of $187.72, signalling upside risk potential of 26.8%. On the other hand Guardant Health has an analysts' consensus of $56.52 which suggests that it could grow by 29.32%. Given that Guardant Health has higher upside potential than Natera, analysts believe Guardant Health is more attractive than Natera.

Natera has a beta of 1.804, which suggesting that the stock is 80.37% more volatile than S&P 500. In comparison Guardant Health has a beta of 1.448, suggesting its more volatile than the S&P 500 by 44.847%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

Natera quarterly revenues are $476.1M, which are larger than Guardant Health quarterly revenues of $201.8M. Natera's net income of -$53.8M is higher than Guardant Health's net income of -$111M. Notably, Natera's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 10.88x versus 7.26x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -11.3% compared to Natera's net margin of 16.94%. Natera's return on equity of -21.3% beat Illumina's return on equity of -35.09%.

Natera has a consensus price target of $187.72, signalling upside risk potential of 26.8%. On the other hand Illumina has an analysts' consensus of $123.72 which suggests that it could grow by 65.45%. Given that Illumina has higher upside potential than Natera, analysts believe Illumina is more attractive than Natera.

Natera has a beta of 1.804, which suggesting that the stock is 80.37% more volatile than S&P 500. In comparison Illumina has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.551%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Natera quarterly revenues are $476.1M, which are smaller than Illumina quarterly revenues of $1.1B. Natera's net income of -$53.8M is lower than Illumina's net income of $187M. Notably, Natera's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 10.88x versus 2.72x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -11.3% compared to Natera's net margin of -14.37%. Natera's return on equity of -21.3% beat Star Equity Holdings's return on equity of -17.45%.

Natera has a consensus price target of $187.72, signalling upside risk potential of 26.8%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 400%. Given that Star Equity Holdings has higher upside potential than Natera, analysts believe Star Equity Holdings is more attractive than Natera.

Natera has a beta of 1.804, which suggesting that the stock is 80.37% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.205%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Natera quarterly revenues are $476.1M, which are larger than Star Equity Holdings quarterly revenues of $17.1M. Natera's net income of -$53.8M is lower than Star Equity Holdings's net income of -$2.5M. Notably, Natera's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 10.88x versus 0.12x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.